Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» COPD
COPD
Sanofi, Regeneron eye Dupixent label expansion with promising COPD data
Sanofi, Regeneron eye Dupixent label expansion with promising COPD data
Medical Marketing and Media
Sanofi
Regeneron
Dupixent
clinical trials
COPD
Flag link:
Viatris and Theravance report data from COPD treatment trial
Viatris and Theravance report data from COPD treatment trial
Clinical Trials Arena
Viatris
Theravance
clinical trials
Yupelri
COPD
Flag link:
Samay’s AI-enabled wearable ‘can diagnose COPD’
Samay’s AI-enabled wearable ‘can diagnose COPD’
Pharmaphorum
Medtech
diagnostics
Samay
Sylvee
artificial intelligence
COPD
Flag link:
FDA warns AstraZeneca over false advertising of COPD drug
FDA warns AstraZeneca over false advertising of COPD drug
Beckers Hospital Review
AstraZeneca
COPD
FDA
Breztri Aerosphere
DTC advertising
Flag link:
Sanofi, Regeneron flesh out COPD data with Dupixent
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Sanofi
Regeneron
COPD
Dupixent
Flag link:
Aer Therapeutics Raises $36M for Novel Approach to COPD
Aer Therapeutics Raises $36M for Novel Approach to COPD
BioSpace
Aer Therapeutics
COPD
funding
Flag link:
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
Sanofi and Regeneron face a high-risk test for Dupixent
Sanofi and Regeneron face a high-risk test for Dupixent
EP Vantage
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data
Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data
BioSpace
Verona Pharma
COPD
ensifentrine
Flag link:
AstraZeneca, C4XD sign exclusive $402 million global license
AstraZeneca, C4XD sign exclusive $402 million global license
Pharmaphorum
AstraZeneca
C4XD
drug development
COPD
Flag link:
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
Yahoo/Benzinga
United Therapeutics
Tyvaso
COPD
clinical trials
Flag link:
EpiEndo begins trial of chronic obstructive pulmonary disease treatment
EpiEndo begins trial of chronic obstructive pulmonary disease treatment
Clinical Trials Arena
EpiEndo Pharmaceuticals
COPD
EP395
Flag link:
On heels of positive COPD readout, Verona to provide new public offering
On heels of positive COPD readout, Verona to provide new public offering
Endpoints
Verona Pharma
COPD
clinical trials
Flag link:
Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026
Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026
BioSpace
Novartis
asthma
COPD
Flag link:
Transpire Bio signs with Recipharm for inhaled medicine development
Transpire Bio signs with Recipharm for inhaled medicine development
European Pharmaceutical Review
Transpire Bio
Recipharm
asthma
COPD
inhaled drugs
drug development
Flag link:
AstraZeneca continues to build out its presence in China with new COPD drug manufacturing site
AstraZeneca continues to build out its presence in China with new COPD drug manufacturing site
Endpoints
AstraZeneca
China
COPD
drug manufacturing
Flag link:
Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program
Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program
Fierce Biotech
Kaleido Biosciences
layoffs
clinical trials
COPD
Flag link:
Viatris gets shot to shed infringement claims in long-running patent kerfuffle on AstraZeneca's Symbicort
Viatris gets shot to shed infringement claims in long-running patent kerfuffle on AstraZeneca's Symbicort
Fierce Pharma
Viatris
generics
Symbicort
AstraZeneca
patents
COPD
asthma
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »